Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eurand concludes Zentase bioavailability study
Results from the study will be included in Eurand’s new drug application (NDA) for Zentase. Eurand initiated its rolling NDA submission in June 2007 and has been granted
Results from the study will be included in Eurand’s new drug application (NDA) for Zentase. Eurand initiated its rolling NDA submission in June 2007 and has been granted
These filings are necessary prior to the anticipated global roll-out of the company’s BioNanoChannel rapid bacteria/microorganism detection technology and also contribute to the protection of NanoLogix’s ongoing Hydrogen
This proof-of-concept study is designed to enroll a total of 180 patients with 120 patients randomized to treatment with retigabine and 60 randomized to placebo treatment for a
The drug, Rh-Apo2L, is produced by genetic engineering and is designed as a highly targeted therapy with direct function on cancer cells. Shanghai Qiaer, Aida’s research subsidiary, has
The study hypothesized that because adhesion of leukemic cells to vascular cells may confer resistance to chemotherapeutic agents, treatment with CA4P would promote leukemic cell death by disrupting
The trial was designed to evaluate the pharmacokinetic and pharmacodynamic response of octreotide implants in patients with acromegaly. The trial evaluated the release effectiveness of both pre-hydrated and
The new drug application (NDA) was submitted by Vanda Pharmaceuticals and includes data from 35 clinical trials and more than 3,000 patients treated with iloperidone. Acceptance of the
The named patient access program (NPAP) is a compassionate use drug supply program administered by the Therapeutic Goods Administration (TGA), under which medical practitioners can legally supply investigational
The study findings demonstrate Hedrin’s superior efficacy compared to malathion, a widely used insecticide treatment in both Europe and North America. These results appeared in the November issue
This blinded, placebo-controlled study assessed symptom scores and treatment outcome two years (range 16 to 27 months) after a single treatment with NX-1207 or placebo. For patients with